Search

Your search keyword '"Brouwers, Adrienne H."' showing total 502 results
Start Over Author "Brouwers, Adrienne H."
502 results on '"Brouwers, Adrienne H."'

152. Increased Risk of Atrial Fibrillation After Treatment for Differentiated Thyroid Carcinoma

Author

Klein Hesselink, Esther N., primary, Lefrandt, Joop D., additional, Schuurmans, Edwin P., additional, Burgerhof, Johannes G. M., additional, Groen, Bart, additional, Gansevoort, Ron T., additional, van der Horst-Schrivers, Anouk N. A., additional, Dullaart, Robin P. F., additional, Van Gelder, Isabelle C., additional, Brouwers, Adrienne H., additional, Rienstra, Michiel, additional, and Links, Thera P., additional

Published
2015
Full Text
View/download PDF

153. 124I PET/CT to Predict the Outcome of Blind 131I Treatment in Patients with Biochemical Recurrence of Differentiated Thyroid Cancer: Results of a Multicenter Diagnostic Cohort Study (THYROPET)

Author

Kist, Jakob W., primary, de Keizer, Bart, additional, van der Vlies, Manfred, additional, Brouwers, Adrienne H., additional, Huysmans, Dyde A., additional, van der Zant, Friso M., additional, Hermsen, Rick, additional, Stokkel, Marcel P.M., additional, Hoekstra, Otto S., additional, and Vogel, Wouter V., additional

Published
2015
Full Text
View/download PDF

155. False-positive findings on 6-[18F]fluor-l-3,4- dihydroxyphenylalanine PET (18F-FDOPA-PET) performed for imaging of neuroendocrine tumors.

Author

Berends, Annika M. A., Kerstens, Michiel N., Bolt, Janne W., Links, Thera P., Korpershoek, Esther, de Krijger, Ronald R., Walenkamp, Annemiek M. E., Noordzij, Walter, van Etten, Boudewijn, Kats-Ugurlu, Gursah, Brouwers, Adrienne H., and van der Horst-Schrivers, Anouk N. A.

Subjects
NEUROENDOCRINE tumors, DOPA, POSITRON emission tomography, DIAGNOSIS
Abstract

Background/aim: PET with 6-[18F]fluor-l-3,4-dihydroxyphenylalanine (18F-FDOPA) has been shown to be a useful imaging tool with a high sensitivity for the visualization of neuroendocrine tumors (NETs). 18F-FDOPA uptake in tumors other than NETs has been suggested previously, but data on this phenomenon are limited. We therefore studied the non-physiological, false-positive uptake of 18F-FDOPA in a large population of patients with a NET or with a high clinical suspicion of harboring a NET. Patients and methods: Retrospective single-center study among adult patients in whom 18F-FDOPA PET scintigraphy was performed between January 2004 and December 2014. The original scan report was compared with the original pathology report corresponding with the 18F-FDOPA PET-positive lesion. In case this was inconsistent with the diagnosis of a NET, both the scan and the pathology slides were reassessed. Specimens of these non-NET tissues were immunohistochemically stained for AADC. Results: 1070 18F-FDOPA PET scans from 705 patients were evaluated. Focal or multiple 18F-FDOPA-avid lesions were described in 709 18F-FDOPA PET scans (66%). Histology of these 18F-FDOPA PET-positive lesions was present in 508 (72%) cases. In seven cases, the histopathology was not compatible with NET but showed squamous cell carcinoma of the cervix, multiple myeloma (two cases), hepatocellular carcinoma, Schwannoma, adrenocortical carcinoma and a skeletal myxoid chondrosarcoma, with positive immunohistochemical staining for AADC in 67%. Conclusions: Pathological uptake of 18F-FDOPA does not always indicate the presence of a NET. The possibility of 18F-FDOPA uptake by tumor types other than NETs, although rare, should be considered. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

156. Positronemissietomografie van [ 89Zr]trastuzumab bij patiënten met gemetastaseerde HER2-positieve borstkanker

Author

Dijkers, Eli C.F., Munnink, Thijs H.Oude, De Vries, Elisabeth G.E., Brouwers, Adrienne H., Jager, Pieter L., De Jong, Johan R., Van Dongen, Guus A.M.S., Schröder, Carolina P., Lub-De Hooge, Marjolijn N., Kosterink, Jos G.W., Otolaryngology / Head & Neck Surgery, and CCA - Disease profiling

Subjects
skin and connective tissue diseases, neoplasms
Abstract

To investigate the use of [ 89Zr]trastuzumab for high-resolution, quantitative and sensitive HER2 PET imaging. A feasibility study was performed to determine optimal conditions of [ 89Zr]trastu-zumab dosage and timing of scans for visualization and quantification of HER2-positive lesions. DESIGN AND METHODS HER2-positive metastatic breast cancer patients received 37 MBq [ 89Zr]trastuzumab at three doses of trastuzumab: 10 or 50 mg when trastuzumab-naive and 10 mg trastuzumab while on trastuzumab treatment. Patients underwent ≥ PET scans around day 2 and 5 after [ 89Zr] trastuzumab injection. RESULTS 14 patients were included. The optimal moment to assess [ 89Zr]-trastuzumab tumour uptake was 4-5 days after tracer injection. Trastuzumab-naive patients required 50 mg [ 89Zr] trastuzumab and for patients on trastuzumab treatment 10 mg was adequate. [ 89Zr]trastuzumab PET imaging detected not only most of the known tumour lesions in liver, lung, bone and brain, but also unknown brain and bone lesions. The relative uptake values (mean ± SD) in liver, bone and brain lesions were 12.8 ± 5.8, 4.1 ± 1.6 and 3.5 ± 4.2, respectively, while relative uptake values in normal liver, spleen, kidneys and brain were 5.9 ± 4.2,2.8 ± 0.7, 4.0 ± 0.7 and 0.20 ± 0.1, respectively. CONCLUSION PET imaging of HER2 with [ 89Zr] trastuzumab can identify HER2-positive lesions in patients with HER2-positive metastatic breast cancer, when an appropriate antibody dose is used. In addition it allows quantification of [ 89Zr]trastuzumab uptake in these lesions.

Published
2012

157. [89Zr]trastuzumab for PET imaging of HER2-positive lesions in patients with metastatic breast cancer

Author

Dijkers, Eli C.F., Munnink, Thijs H. Oude, De Vries, Elisabeth G.E., Brouwers, Adrienne H., Jager, Pieter L., De Jong, Johan R., Van Dongen, Guus A.M.S., Schröder, Carolina P., Lub-De Hooge, Marjolijn N., Kosterink, Jos G.W., Guided Treatment in Optimal Selected Cancer Patients (GUTS), Biopharmaceuticals, Discovery, Design and Delivery (BDDD), and Targeted Gynaecologic Oncology (TARGON)

Subjects
cancer patient, clinical article, liver tumor, positron emission tomography, article, zirconium, feasibility study, bone tumor, lung tumor, trastuzumab, breast cancer, dose response, drug tumor level, human, skin and connective tissue diseases, neoplasms, outcome assessment, brain tumor
Abstract

To investigate the use of [89Zr]trastuzumab for high-resolution, quantitative and sensitive HER2 PET imaging. A feasibility study was performed to determine optimal conditions of [89Zr]trastu-zumab dosage and timing of scans for visualization and quantification of HER2-positive lesions. DESIGN AND METHODS HER2-positive metastatic breast cancer patients received 37 MBq [89Zr]trastuzumab at three doses of trastuzumab: 10 or 50 mg when trastuzumab-naive and 10 mg trastuzumab while on trastuzumab treatment. Patients underwent ≥ PET scans around day 2 and 5 after [89Zr] trastuzumab injection. RESULTS 14 patients were included. The optimal moment to assess [89Zr]-trastuzumab tumour uptake was 4-5 days after tracer injection. Trastuzumab-naive patients required 50 mg [89Zr] trastuzumab and for patients on trastuzumab treatment 10 mg was adequate. [ 89Zr]trastuzumab PET imaging detected not only most of the known tumour lesions in liver, lung, bone and brain, but also unknown brain and bone lesions. The relative uptake values (mean ± SD) in liver, bone and brain lesions were 12.8 ± 5.8, 4.1 ± 1.6 and 3.5 ± 4.2, respectively, while relative uptake values in normal liver, spleen, kidneys and brain were 5.9 ± 4.2,2.8 ± 0.7, 4.0 ± 0.7 and 0.20 ± 0.1, respectively. CONCLUSION PET imaging of HER2 with [89Zr] trastuzumab can identify HER2-positive lesions in patients with HER2-positive metastatic breast cancer, when an appropriate antibody dose is used. In addition it allows quantification of [89Zr]trastuzumab uptake in these lesions.

Published
2012

159. Recombinant TSH Stimulated Remnant Ablation Therapy in Thyroid Cancer: The Success Rate Depends on the Definition of Ablation Success—An Observational Study

Author

van der Horst-Schrivers, Anouk N. A., primary, Sluiter, Wim J., additional, Muller Kobold, Anneke C., additional, Wolffenbuttel, Bruce H. R., additional, Plukker, John T. M., additional, Bisschop, Peter H., additional, de Klerk, John M., additional, Al Younis, Imad, additional, Lips, Paul, additional, Smit, Jan W., additional, Brouwers, Adrienne H., additional, and Links, Thera P., additional

Published
2015
Full Text
View/download PDF

160. EUS is superior for detection of pancreatic lesions compared with standard imaging in patients with multiple endocrine neoplasia type 1

Author

van Asselt, Sophie J., primary, Brouwers, Adrienne H., additional, van Dullemen, Hendrik M., additional, van der Jagt, Eric J., additional, Bongaerts, Alfons H.H., additional, Kema, Ido P., additional, Koopmans, Klaas P., additional, Valk, Gerlof D., additional, Timmers, Henri J., additional, de Herder, Wouter W., additional, Feelders, Richard A., additional, Fockens, Paul, additional, Sluiter, Wim J., additional, de Vries, Elisabeth G.E., additional, and Links, Thera P., additional

Published
2015
Full Text
View/download PDF

161. Multidrug resistance in oncology and beyond: from imaging of drug efflux pumps to cellular drug targets

Author

Nagengast, Wouter B, Oude Munnink, Thijs H, Dijkers, Eli, Hospers, Geesiena, Brouwers, Adrienne H, Schröder, Carolien P, Lub-de Hooge, Marjolijn, de Vries, Elisabeth G E, and Guided Treatment in Optimal Selected Cancer Patients (GUTS)

Subjects
Vascular Endothelial Growth Factor A, Receptor, ErbB-2, Neoplasms, P-Glycoprotein, Animals, Humans, Antineoplastic Agents, Multidrug Resistance-Associated Proteins, Radionuclide Imaging, Drug Resistance, Multiple
Abstract

Resistance of tumor cells to several structurally unrelated classes of natural products, including anthracyclines, taxanes, and epipodophyllotoxines, is often referred as multidrug resistance (MDR). This is associated with ATP-binding cassette transporters, which function as drug efflux pumps such as P-glycoprotein (Pgp) and multidrug resistance-associated protein 1 (MRP1). Because of the hypothesis in the early eighties that blockade of these efflux pumps by modulators would improve the effect of chemotherapy, extensive effort has been put to visualize these pumps using nuclear imaging with several specific tracers, using both SPECT and PET techniques. The methods and possibilities to visualize these pumps in both the tumor and the blood-brain barrier will be discussed. Because of the fact that the addition of Pgp or MRP modulators has not shown any clinical benefit in patient outcome, these specific MDR tracers are not routinely used in clinical practice. Evidence emerges that combination of chemotherapeutic drugs involved in MDR with the so-called targeted agents can improve patient outcome. The concept of molecular imaging can also be used to visualize the targets for these agents, such as HER2/neu and angiogenic factors such as vascular endothelial growth factor (VEGF). Potentially visualizing molecular drug targets in the tumor can function as biomarkers to support treatment decision for the individual patient.

Published
2010

162. Medullair schildkliercarcinoom, een tumor met vele gezichten

Author

Verbeek, Hans H G, de Groot, Jan Willem B, Plukker, John T M, Hofstra, Robert W M, Brouwers, Adrienne H, Kerstens, Michiel N, Links, Thera P, Damage and Repair in Cancer Development and Cancer Treatment - 1, and Guided Treatment in Optimal Selected Cancer Patients

Subjects
Adult, Aged, 80 and over, endocrine system diseases, Middle Aged, Diagnosis, Differential, Pyrimidines, Treatment Outcome, Positron-Emission Tomography, Humans, Pyrazoles, Female, Thyroid Neoplasms, Thyroid Nodule, Enzyme Inhibitors, Neoplasm Metastasis
Abstract

Medullary thyroid cancer (MTC) has a variable clinical presentation. We present 3 patients with this endocrine tumour. The first patient, a 41-year-old woman complaining of diarrhoea, a painful abdomen, weight loss and sensibility disorders in both legs, had metastases of MTC in the spine, with little progression during 2 years of follow-up. The second patient, a 64-year-old woman suffering from a painful nodule in the neck and a painful shoulder, was diagnosed with MTC and liver, lung and bone metastases. She died after 14 months due to progressive disease. The third patient, an 81-year-old woman with hyperparathyroidism, was coincidentally diagnosed with MTC after goitre surgery at the age of 67. When she was evaluated for rising calcitonin levels, a pheochromocytoma was found. RET mutation analysis confirmed a MEN2A syndrome. Current diagnostic procedures of MTC may include positron emission tomography with 18F-deoxyglucose (FDG-PET) and 18F-diphenylalanine (DOPA-PET). MTC is usually treated surgically. Tyrosine kinase inhibitors appear to offer potential new therapeutic possibilities.

Published
2010

163. In Vivo Biodistribution of No-Carrier-Added 6-18F-Fluoro-3,4-Dihydroxy-l-Phenylalanine (18F-DOPA), Produced by a New Nucleophilic Substitution Approach, Compared with Carrier-Added 18F-DOPA, Prepared by Conventional Electrophilic Substitution

Author

Kuik, Willem-Jan, primary, Kema, Ido P., additional, Brouwers, Adrienne H., additional, Zijlma, Rolf, additional, Neumann, Kiel D., additional, Dierckx, Rudi A.J.O., additional, DiMagno, Stephen G., additional, and Elsinga, Philip H., additional

Published
2014
Full Text
View/download PDF

164. 89Zr-Bevacizumab PET Visualizes Heterogeneous Tracer Accumulation in Tumor Lesions of Renal Cell Carcinoma Patients and Differential Effects of Antiangiogenic Treatment

Author

Oosting, Sjoukje F., primary, Brouwers, Adrienne H., additional, van Es, Suzanne C., additional, Nagengast, Wouter B., additional, Oude Munnink, Thijs H., additional, Lub-de Hooge, Marjolijn N., additional, Hollema, Harry, additional, de Jong, Johan R., additional, de Jong, Igle J., additional, de Haas, Sanne, additional, Scherer, Stefan J., additional, Sluiter, Wim J., additional, Dierckx, Rudi A., additional, Bongaerts, Alfons H.H., additional, Gietema, Jourik A., additional, and de Vries, Elisabeth G.E., additional

Published
2014
Full Text
View/download PDF

168. 89Zr-trastuzumab and 89Zr-bevacizumab PET to Evaluate the Effect of the HSP90 Inhibitor NVP-AUY922 in Metastatic Breast Cancer Patients

Author

Gaykema, Sietske B.M., primary, Schröder, Carolien P., additional, Vitfell-Rasmussen, Joanna, additional, Chua, Sue, additional, Oude Munnink, Thijs H., additional, Brouwers, Adrienne H., additional, Bongaerts, Alfons H.H., additional, Akimov, Mikhail, additional, Fernandez-Ibarra, Cristina, additional, Lub-de Hooge, Marjolijn N., additional, de Vries, Elisabeth G.E., additional, Swanton, Charles, additional, and Banerji, Udai, additional

Published
2014
Full Text
View/download PDF

169. 111 In-Trastuzumab Scintigraphy in HER2-Positive Metastatic Breast Cancer Patients Remains Feasible during Trastuzumab Treatment

Author

Gaykema, Sietske B.M., primary, de Jong, Johan R., additional, Perik, Patrick J., additional, Brouwers, Adrienne H., additional, Schröder, Carolien P., additional, Munnink, Thijs H. Oude, additional, Bongaerts, Alphons H.H., additional, de Vries, Elisabeth G.E., additional, and Hooge, Marjolijn N. Lub-de, additional

Published
2014
Full Text
View/download PDF

170. Phase I imaging study of the HER3 antibody RG7116 using 89Zr-RG7116-PET in patients with metastatic or locally advanced HER3-positive solid tumors.

Author

Bensch, Frederike, primary, Lamberts, Laetitia E., additional, Lub-de Hooge, Marjolijn N., additional, Terwisscha van Scheltinga, Anton G.T., additional, de Jong, Johan R., additional, Gietema, Jourik A., additional, Schroder, Carolien P., additional, Smeenk, Michiel M., additional, Jacob, Wolfgang, additional, Abiraj, Keelara, additional, Wolf, Michaela, additional, Adessi, Celine, additional, Meneses-Lorente, Georgina, additional, Zajac, Magdalena, additional, Weisser, Martin, additional, Brouwers, Adrienne H., additional, and De Vries, Elisabeth, additional

Published
2014
Full Text
View/download PDF

171. PET/CT with 89Zr-trastuzumab and 18F-FDG to individualize treatment with trastuzumab emtansine (T-DM1) in metastatic HER2-positive breast cancer (mBC).

Author

Gebhart, Geraldine, primary, Lamberts, Laetitia E., additional, Garcia, Camilo, additional, Ameye, Lieveke, additional, Stroobants, Sigrid, additional, Huizing, Manon, additional, Aftimos, Philippe G., additional, Tol, Jolien, additional, Oyen, Wim J.G., additional, Wimana, Zena, additional, Dongen, G.A.M.S. van, additional, Hoekstra, Otto S., additional, Schroder, Carolien P., additional, Gaye, Julie, additional, Menke, Catharina Wilhelmina, additional, Guiot, Thomas, additional, Brouwers, Adrienne H., additional, Awada, Ahmad, additional, de Vries, Elisabeth G. E., additional, and Flamen, Patrick, additional

Published
2014
Full Text
View/download PDF

172. 89Zr-bevacizumab PET imaging of disease manifestations in patients with Von Hippel-Lindau disease.

Author

Oosting, Sjoukje, primary, Van Asselt, Sophie J., additional, Brouwers, Adrienne H., additional, Bongaerts, Alfons H. H., additional, Steinberg, Julia, additional, de Jong, Johan R., additional, Lub-de Hooge, Marjolijn N., additional, Van der Horst-Schrivers, Anouk N.A., additional, Walenkamp, Anna Maria Elisabeth, additional, Hoving, Eelco W., additional, Sluiter, Wim J., additional, Zonnenberg, B. A., additional, De Vries, Elisabeth, additional, and Links, Thera P., additional

Published
2014
Full Text
View/download PDF

173. Everolimus Reduces 89Zr-Bevacizumab Tumor Uptake in Patients with Neuroendocrine Tumors

Author

van Asselt, Sophie J., primary, Oosting, Sjoukje F., additional, Brouwers, Adrienne H., additional, Bongaerts, Alfons H.H., additional, de Jong, Johan R., additional, Lub-de Hooge, Marjolijn N., additional, Oude Munnink, Thijs H., additional, Fiebrich, Helle-Brit, additional, Sluiter, Wim J., additional, Links, Thera P., additional, Walenkamp, Annemiek M.E., additional, and de Vries, Elisabeth G.E., additional

Published
2014
Full Text
View/download PDF

175. 18-Fluorodeoxyglucose Positron Emission Tomography in the Early Diagnostic Workup of Differentiated Thyroid Cancer Patients with a Negative Post-Therapeutic Iodine Scan and Detectable Thyroglobulin

Author

van Dijk, Deborah, primary, Plukker, John T.M., additional, Phan, Ha T.T., additional, Muller Kobold, Anneke C., additional, van der Horst-Schrivers, Anouk N.A., additional, Jansen, Liesbeth, additional, Sluiter, Wim J., additional, Brouwers, Adrienne H., additional, and Links, Thera P., additional

Published
2013
Full Text
View/download PDF

176. 89Zr-Bevacizumab PET Imaging in Primary Breast Cancer

Author

Gaykema, Sietske B.M., primary, Brouwers, Adrienne H., additional, Lub-de Hooge, Marjolijn N., additional, Pleijhuis, Rick G., additional, Timmer-Bosscha, Hetty, additional, Pot, Linda, additional, van Dam, Gooitzen M., additional, van der Meulen, Sibylle B., additional, de Jong, Johan R., additional, Bart, Joost, additional, de Vries, Jakob, additional, Jansen, Liesbeth, additional, de Vries, Elisabeth G.E., additional, and Schröder, Carolien P., additional

Published
2013
Full Text
View/download PDF

182. 89 Zr-bevacizumab PET imaging in metastatic renal cell carcinoma patients before and during antiangiogenic treatment.

Author

Oosting, Sjoukje, primary, Brouwers, Adrienne H., additional, Van Es, Suzanne C., additional, Nagengast, Wouter B., additional, Oude Munnink, Thijs H., additional, Lub-de Hooge, Marjolijn N., additional, Hollema, Harry, additional, De Jong, Johan R, additional, de Jong, Igle J., additional, de Haas, Sanne, additional, Scherer, Stefan, additional, Sluiter, Wim J., additional, Dierckx, Rudi A, additional, Bongaerts, A. H.H., additional, Gietema, Jourik A., additional, and De Vries, Elisabeth, additional

Published
2012
Full Text
View/download PDF

186. Long-Term Quality of Life in Adult Survivors of Pediatric Differentiated Thyroid Carcinoma.

Author

Nies, Marloes, Klein Hesselink, Mariëlle S, Huizinga, Gea A, Sulkers, Esther, Brouwers, Adrienne H, Burgerhof, Johannes G M, van Dam, Eveline W C M, Havekes, Bas, van den Heuvel-Eibrink, Marry M, Corssmit, Eleonora P M, Kremer, Leontien C M, Netea-Maier, Romana T, van der Pal, Heleen J H, Peeters, Robin P, Plukker, John T M, Ronckers, Cécile M, van Santen, Hanneke M, Tissing, Wim J E, Links, Thera P, and Bocca, Gianni

Abstract

Little is known about long-term quality of life (QoL) of survivors of pediatric differentiated thyroid carcinoma. Therefore, this study aimed to evaluate generic health-related QoL (HRQoL), fatigue, anxiety, and depression in these survivors compared with matched controls, and to evaluate thyroid cancer-specific HRQoL in survivors only.

Published
2017
Full Text
View/download PDF

187. Extending the clinical capabilities of short- and long-lived positron-emitting radionuclides through high sensitivity PET/CT

Author

van Sluis, Joyce, Borra, Ronald, Tsoumpas, Charalampos, van Snick, Johannes H., Roya, Mostafa, ten Hove, Dik, Brouwers, Adrienne H., Lammertsma, Adriaan A., Noordzij, Walter, Dierckx, Rudi A.J.O., Slart, Riemer H.J.A., and Glaudemans, Andor W.J.M.

Abstract

This review describes the main benefits of using long axial field of view (LAFOV) PET in clinical applications. As LAFOV PET is the latest development in PET instrumentation, many studies are ongoing that explore the potentials of these systems, which are characterized by ultra-high sensitivity. This review not only provides an overview of the published clinical applications using LAFOV PET so far, but also provides insight in clinical applications that are currently under investigation. Apart from the straightforward reduction in acquisition times or administered amount of radiotracer, LAFOV PET also allows for other clinical applications that to date were mostly limited to research, e.g., dual tracer imaging, whole body dynamic PET imaging, omission of CT in serial PET acquisition for repeat imaging, and studying molecular interactions between organ systems. It is expected that this generation of PET systems will significantly advance the field of nuclear medicine and molecular imaging.

Published
2022
Full Text
View/download PDF

188. VEGF-SPECT with 111In-bevacizumab in stage III/IV melanoma patients

Author

Nagengast, Wouter B., primary, Hooge, Marjolijn N. Lub-de, additional, van Straten, Esther M.E., additional, Kruijff, Schelto, additional, Brouwers, Adrienne H., additional, den Dunnen, Wilfred F.A., additional, de Jong, Johan R., additional, Hollema, Harry, additional, Dierckx, Rudi A., additional, Mulder, Nanno H., additional, de Vries, Elisabeth G.E., additional, Hoekstra, Harald J., additional, and Hospers, Geke A.P., additional

Published
2011
Full Text
View/download PDF

191. VEGF-PET Imaging Is a Noninvasive Biomarker Showing Differential Changes in the Tumor during Sunitinib Treatment

Author

Nagengast, Wouter B., primary, Lub-de Hooge, Marjolijn N., additional, Oosting, Sjoukje F., additional, den Dunnen, Wilfred F.A., additional, Warnders, Frank-Jan, additional, Brouwers, Adrienne H., additional, de Jong, Johan R., additional, Price, Patricia M., additional, Hollema, Harry, additional, Hospers, Geke A.P., additional, Elsinga, Philip H., additional, Hesselink, Jan Willem, additional, Gietema, Jourik A., additional, and de Vries, Elisabeth G.E., additional

Published
2011
Full Text
View/download PDF

194. Prospective Comparison of [18F]Fluorodeoxyglucose Positron Emission Tomography and Computed Tomography in Patients With Melanoma With Palpable Lymph Node Metastases: Diagnostic Accuracy and Impact on Treatment

Author

Bastiaannet, Esther, primary, Wobbes, Theo, additional, Hoekstra, Otto S., additional, van der Jagt, Eric J., additional, Brouwers, Adrienne H., additional, Koelemij, Ron, additional, de Klerk, John M.H., additional, Oyen, Wim J.G., additional, Meijer, Sybren, additional, and Hoekstra, Harald J., additional

Published
2009
Full Text
View/download PDF

196. In Reply

Author

Kema, Ido P., primary, Koopmans, Klaas-Pieter, additional, Elsinga, Philip H., additional, Brouwers, Adrienne H., additional, Jager, Pieter L., additional, and de Vries, Elisabeth G.E., additional

Published
2008
Full Text
View/download PDF

198. Manipulation of [11C]-5-Hydroxytryptophan and 6-[18F]Fluoro-3,4-Dihydroxy-l-Phenylalanine Accumulation in Neuroendocrine Tumor Cells

Author

Neels, Oliver C., primary, Koopmans, Klaas P., additional, Jager, Pieter L., additional, Vercauteren, Laya, additional, van Waarde, Aren, additional, Doorduin, Janine, additional, Timmer-Bosscha, Hetty, additional, Brouwers, Adrienne H., additional, de Vries, Elisabeth G.E., additional, Dierckx, Rudi A.J.O., additional, Kema, Ido P., additional, and Elsinga, Philip H., additional

Published
2008
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results